Literature DB >> 15006483

Schizophrenia as a disorder of neuroplasticity.

Robert E McCullumsmith1, Sarah M Clinton, James H Meador-Woodruff.   

Abstract

Schizophrenia is a devastating mental illness affecting millions worldwide with significant financial and emotional burdens for afflicted persons, their families, and society. Considering schizophrenia as a disorder of neuroplasticity permits integration of competing neurochemical and neurodevelopmental hypotheses. Recent advances have linked the pathophysiology of schizophrenia with abnormalities of the glutamate neurotransmitter system. Elements of glutamergic neurotransmission implicated in schizophrenia, including glutamate receptors and receptor-associated molecules, have critical roles in long-term potentiation, a molecular correlate of neuroplasticity. We suggest that schizophrenia can be considered a disorder of plasticity, associated with molecular abnormalities of the glutamate synapse.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15006483     DOI: 10.1016/S0074-7742(04)59002-5

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  26 in total

1.  Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder.

Authors:  Robert E McCullumsmith; Lars V Kristiansen; Monica Beneyto; Elizabeth Scarr; Brian Dean; James H Meador-Woodruff
Journal:  Brain Res       Date:  2006-11-17       Impact factor: 3.252

Review 2.  Control of ACTH secretion by excitatory amino acids: functional significance and clinical implications.

Authors:  Daniela Jezova
Journal:  Endocrine       Date:  2005-12       Impact factor: 3.633

3.  Expression of equilibrative nucleoside transporter type 1 protein in elderly patients with schizophrenia.

Authors:  Dan Shan; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Neuroreport       Date:  2012-03-07       Impact factor: 1.837

4.  Altered serine/threonine kinase activity in schizophrenia.

Authors:  Jennifer L McGuire; John H Hammond; Stefani D Yates; Dongquan Chen; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Brain Res       Date:  2014-04-26       Impact factor: 3.252

5.  Adolescent stress leads to glutamatergic disturbance through dopaminergic abnormalities in the prefrontal cortex of genetically vulnerable mice.

Authors:  Yurie Matsumoto; Minae Niwa; Akihiro Mouri; Yukihiro Noda; Takeshi Fukushima; Norio Ozaki; Toshitaka Nabeshima
Journal:  Psychopharmacology (Berl)       Date:  2017-07-29       Impact factor: 4.530

6.  Endosomal trafficking of AMPA receptors in frontal cortex of elderly patients with schizophrenia.

Authors:  John C Hammond; Robert E McCullumsmith; Vahram Haroutunian; James H Meador-Woodruff
Journal:  Schizophr Res       Date:  2011-05-14       Impact factor: 4.939

Review 7.  Postmortem brain: an underutilized substrate for studying severe mental illness.

Authors:  Robert E McCullumsmith; John H Hammond; Dan Shan; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2013-10-04       Impact factor: 7.853

8.  Altered vesicular glutamate transporter expression in the anterior cingulate cortex in schizophrenia.

Authors:  Akin Oni-Orisan; Lars V Kristiansen; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Biol Psychiatry       Date:  2007-12-26       Impact factor: 13.382

9.  Disrupted-in-Schizophrenia 1 (DISC1) regulates spines of the glutamate synapse via Rac1.

Authors:  Akiko Hayashi-Takagi; Manabu Takaki; Nick Graziane; Saurav Seshadri; Hannah Murdoch; Allan J Dunlop; Yuichi Makino; Anupamaa J Seshadri; Koko Ishizuka; Deepak P Srivastava; Zhong Xie; Jay M Baraban; Miles D Houslay; Toshifumi Tomoda; Nicholas J Brandon; Atsushi Kamiya; Zhen Yan; Peter Penzes; Akira Sawa
Journal:  Nat Neurosci       Date:  2010-02-07       Impact factor: 24.884

10.  Cortical development and glutamatergic dysregulation in schizophrenia.

Authors:  Akira Sawa
Journal:  Biol Psychiatry       Date:  2009-09-15       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.